Clinical Trials Browser

Phase 1/2 × INDUSTRY × Niacinamide × Clear all

NCT05296525 2025-03-25

Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL

Phase 1/2 Terminated

13 enrolled 10 charts

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse